José Segura

Hospital Universitario Reina Sofía, Cordoue, Andalusia, Spain

Are you José Segura?

Claim your profile

Publications (85)221.77 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple approach is the predominant strategy for the percutaneous coronary intervention of bifurcation lesions. Performing side branch (SB) predilation in this context is currently a matter of controversy. In this study, we assess the efficacy of SB predilatation before a provisional T-stent strategy for bifurcation lesions.
    American heart journal. 09/2014; 168(3):374-380.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this study was to assess the immediate and long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) in an unprotected distal left main coronary artery (UDLM). PCI for UDLM-ISR can be complex. Limited information is available on procedural and clinical outcomes. Between May 2002 and February 2011, UDLM-ISR after drug-eluting stent implantation was observed in 79 of 1,102 patients (7%). Seventy-five were treated by repeat PCI using a simple approach (balloon/in-stent implantation) or a complex strategy (additional stent/double-stenting technique). A diagnosis of mild or severe restenosis was considered depending on the number of bifurcation segments affected (1 vs. >1). Major adverse cardiac events (MACE) were defined as cardiac death, target lesion revascularization, and myocardial infarction. ISR treatment was performed using a simple approach in 44 (58%) patients, and using a complex strategy in 31 (42%). After 46 ± 26 months, the MACE rate was 22%. Patients treated with a simple approach had a lower incidence of MACE at follow-up compared with patients treated with a complex strategy, regardless of the restenosis extent (mild restenosis: 93% vs. 67%, p < 0.05; severe: 70% vs. 23%, p < 0.05). On Cox regression analysis, diabetes was the only predictor of MACE (hazard ratio [HR]: 4.94; 95% confidence interval [CI]: 1.03 to 23.70; p < 0.05), whereas a simple strategy for ISR treatment was associated with lower risk (HR: 0.25; 95% CI: 0.08 to 0.79; p = 0.02). PCI for UDLM-ISR is safe and feasible, with a high rate of procedural success and an acceptable long-term MACE rate. A simple strategy, when applicable, appears to be a good treatment option, associated with a lower event rate at follow-up.
    JACC. Cardiovascular Interventions 01/2014; · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There have been significant advances in percutaneous interventions for congenital heart disease over the last 30 years. In this first article we will focus on ventricular outflow obstructions. Among left ventricular outflow tract obstructions, stent repair of coarctation of aorta and supravalvular aortic stenosis offer percutaneous solutions. Balloon valvuloplasty for aortic valve stenosis and balloon tearing of a thin discrete subaortic stenosis are also alternatives to surgery. Among right ventricular outflow tract obstructions, balloon valvuloplasty for pulmonary stenosis is currently the gold standard for treatment. For homograft degeneration after surgery of the outflow tract, pulmonary valve implantation (Melody) may avoid further surgical interventions. Stent implantation for pulmonary branch stenosis is the treatment of choice for this congenital disease or post-surgical pathology.
    Cardiocore 07/2013; 48(3):102–112.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction and objectivesDifferent studies have shown improvement in patients with idiopathic nonischemic dilated cardiomyopathy treated with cell-therapy. However, factors influencing responsiveness are not well known. This trial investigates functional changes and factors influencing the 6-month gain in ejection fraction in 27 patients with dilated cardiomiopathy treated with intracoronary cell-therapy.Methods Patients received intracoronary infusion of autologous bone-marrow mononuclear cells (mean infused, 10.2 [2.9]×108). Flow cytometry and functional analyses of the cells were also performed.ResultsThe 6-month angiographic gain in ejection fraction ranged from −9% to 34% (mean, 9%). These changes were distinguished into 2 groups: 21 patients (78%) with a significant improvement at the 6-month evaluation (mean gain, 14 [7]%), and 6 patients who had no response (mean gain, −5 [3]%). The responders were younger as compared to the nonresponders (50 [12] years vs 62 [9] years; P<.04). There was an inverse correlation (r=−0,41; P<.003) between the gain in ejection fraction and the high density lipoprotein level, suggesting higher functional gain with low high density lipoprotein levels. The 24 h migratory capability of the infused cells was significantly reduced in the responders’ group (5.4 [1.7]×108 vs 8.1 [2.3]×108; P<.009 for vascular endothelial growth factor and 5.8 [1.7]×108 vs 8.4 [2.9]×108; P<.002 for stromal cell-derived factor-1).Conclusions Younger patients with dilated cardiomiopathy and lower plasma high density lipoprotein levels gain greater benefit from intracoronary cell-therapy. Functional improvement also seems to be enhanced by a lower migratory capacity of the infused cells.Full English text available from:www.revespcardiol.org/en.
    Revista Española de Cardiología. 06/2013; 66(6):450–457.
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION AND OBJECTIVES: Different studies have shown improvement in patients with idiopathic nonischemic dilated cardiomyopathy treated with cell-therapy. However, factors influencing responsiveness are not well known. This trial investigates functional changes and factors influencing the 6-month gain in ejection fraction in 27 patients with dilated cardiomiopathy treated with intracoronary cell-therapy. METHODS: Patients received intracoronary infusion of autologous bone-marrow mononuclear cells (mean infused, 10.2 [2.9]×10(8)). Flow cytometry and functional analyses of the cells were also performed. RESULTS: The 6-month angiographic gain in ejection fraction ranged from -9% to 34% (mean, 9%). These changes were distinguished into 2 groups: 21 patients (78%) with a significant improvement at the 6-month evaluation (mean gain, 14 [7]%), and 6 patients who had no response (mean gain, -5 [3]%). The responders were younger as compared to the nonresponders (50 [12] years vs 62 [9] years; P<.04). There was an inverse correlation (r=-0,41; P<.003) between the gain in ejection fraction and the high density lipoprotein level, suggesting higher functional gain with low high density lipoprotein levels. The 24h migratory capability of the infused cells was significantly reduced in the responders' group (5.4 [1.7]×10(8) vs 8.1 [2.3]×10(8); P<.009 for vascular endothelial growth factor and 5.8 [1.7]×10(8) vs 8.4 [2.9]×10(8); P<.002 for stromal cell-derived factor-1). CONCLUSIONS: Younger patients with dilated cardiomiopathy and lower plasma high density lipoprotein levels gain greater benefit from intracoronary cell-therapy. Functional improvement also seems to be enhanced by a lower migratory capacity of the infused cells. Full English text available from:www.revespcardiol.org/en.
    Revista Espa de Cardiologia 03/2013; · 3.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant advancements in percutaneous interventions for congenital heart disease have been developed over the last 30 years. In the first article we analyzed ventricular outflow obstruction. In this second part, we will focus on heart defects and shunts. The percutaneous device closure of atrial septal and interventricular defects and the persistent ductus arteriosus in the main left-to-right shunts are safe alternatives to surgical closure. Also central and systemic-to-pulmonary fistulas may be closed percutaneously by specific devices. The right-to-left shunts, such as the patent foramen ovale or surgical fenestrations, can also be closed percutaneously. Finally, for severe left ventricular disfunction in infancy, cell therapy appears promising for the future.
    Cardiocore 01/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: To compare the efficacy of sirolimus- and everolimus-eluting stents in patients with bifurcation lesions treated with provisional side-branch stenting. BACKGROUND: The efficacy of everolimus-eluting stents in bifurcation lesions has been poorly tested. METHODS: Patients with all types of Medina bifurcation lesions were randomly assigned to treatment with either a sirolimus- (n = 145) or everolimus-eluting stent (n = 148). We included patients with main vessel diameter over 2.5 mm and side branches over 2.25 mm. Patients with diffuse side-branch stenosis were excluded. RESULTS: There were no significant differences between patients from the sirolimus and everolimus groups in terms of age, risk factors, clinical status, location of the bifurcation lesions or angiographic variables. Immediate results and in-hospital outcome were also similar in both groups of patients. In-hospital death occurred in two patients, one from each group. Target lesion revascularization was required in nine patients: four patients (2.7%) from the sirolimus group and five patients (3.4%) from the everolimus group. Late cardiac mortality occurred in two patients from the sirolimus group and in one patient from the everolimus group. Major cardiac event rates at 1 year were similar in both groups: nine patients (6.2%) in the sirolimus group and nine patients (6.1%) from the everolimus group (p: ns). CONCLUSIONS: In patients with bifurcation lesions, no significant differences in clinical outcome at 1-year follow-up were observed between sirolimus- and everolimus-eluting stent groups. © 2012 Wiley Periodicals, Inc.
    Catheterization and Cardiovascular Interventions 04/2012; · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is one of the most common neoplasms associated with cardiac metastasis and the pericardium is often affected. However, isolated myocardial involvement in these patients is very uncommon. Most tumor invasions into the heart are nonspecific and clinically silent. Myocardial metastasis rarely mimics an acute myocardial infarction. We report a case of a 59-year old man with a metastatic lung cancer into the myocardium who presented mimicking an acute myocardial infarction.
    The American journal of emergency medicine 12/2011; · 1.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transluminal balloon tearing of the membrane in a thin discrete subaortic stenosis is an alternative to membrane surgical resection. However, the long-term outcome of patients with isolated thin discrete subaortic stenosis treated by transluminal balloon tearing remains unknown. This 25-year study describes findings from 76 patients with isolated thin discrete subaortic stenosis who underwent percutaneous transluminal balloon tearing of the membrane and were followed up for a mean period of 16±6 years. The age at presentation had a wide range (2-67 years). The mean age at treatment was 19±16 years. Immediately after treatment, the subvalvular gradient decreased from 70±27 to 18±12 mm Hg (P<0.001). No significant postprocedural aortic regurgitation was observed. After a mean follow-up time of 16±6 years, 11 patients (15%) developed restenosis, 3 patients (4%) progressed to muscular obstructive disease, and 1 patient (1.3%) developed a new distant obstructive membrane. Twelve patients (16%) were redilated at a mean of 5±3 years after their first treatment, and 4 patients (5%) underwent surgery at a mean of 3±2 years after their first treatment. Fifty-eight patients (77%) remained alive and free of redilation or surgery at follow-up. Larger annulus diameter and thinner membranes were independent factors associated with better long-term results. Most patients (77%) with isolated thin discrete subaortic stenosis treated with transluminal balloon tearing of the membrane had sustained relief at subsequent follow-ups without restenosis, the need for surgery, progression to muscular obstructive disease, or an increase in the degree of aortic regurgitation.
    Circulation 08/2011; 124(13):1461-8. · 15.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Provisional side-branch stenting is currently the most widely accepted percutaneous technique for the treatment of bifurcation lesions. However, abrupt closure of the side branch may occur after main vessel stent implantation. Resolving side-branch stenosis under these conditions may pose major technical difficulties. We describe a new technique to resolve uncrossable side-branch occlusion following main-vessel stent implantation during provisional side-branch stenting. The technique consists of using the jailed wire to dilate the occluded side branch. We first use a low profile, 1.25-mm diameter balloon catheter. A regular balloon is then inflated through the same wire to open the side branch, crushing the proximal part of the main vessel stent. At this point, a second stent is implanted at the side-branch, finishing the procedure as an inverted crush stenting. The described strategy may be useful in cases of uncrossable side-branch occlusion causing severe hemodynamic impairment that cannot be swiftly managed with conventional methods.
    Revista Espa de Cardiologia 04/2011; 64(8):718-22. · 3.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present report compared the incidence of 1-year clinical events in patients with bifurcation lesions that had been treated with a simple approach who were randomized to either a simultaneous final kissing balloon (KB) or an isolated side-branch (SB) balloon post-dilation. From February 2007 to December 2008, 293 patients with all types of Medina bifurcation lesions were enrolled in a prospective study. All patients underwent implantation of a sirolimus- or everolimus-eluting stent across the bifurcation and provisional SB stenting. Patients with no SB ostial compromise or those needing a second stent were excluded from the present study (n = 49). The eligible patients were randomly assigned to treatment with final KB inflation (n = 124, KB group) or isolated balloon after dilation (n = 120, non-KB group). No significant differences were found between the patients from the KB and non-KB groups in terms of age, risk factors, clinical status, or location of the bifurcation lesions. The angiographic data and immediate results were also similar in both groups. Four patients experienced a non-Q-wave acute myocardial infarction in the hospital: three (2%) from the KB group and one (1%) from the non-KB group. Two in-hospital deaths occurred in the non-KB group. Target lesion revascularization was required in 7 patients (3%): 5 from the KB group and 2 from the non-KB group. Late mortality occurred in 3 patients from the KB group and 2 patients from the non-KB group. The incidence of major events at 1 year (death, target lesion revascularization, or acute myocardial infarction) was similar in both groups: 11 (9%) from the KB group and 7 (6%) from the non-KB group (p = NS). In conclusion, no differences in the clinical outcome at 1 year of follow-up were observed between the patients with bifurcation lesions treated with a simple approach and either a simultaneous final KB or an isolated SB balloon post-dilation.
    The American journal of cardiology 03/2011; 107(10):1460-5. · 3.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study investigated echocardiographic findings after 1 month in 22 patients who received a CoreValve prostheses to treat aortic valve stenosis. Particular attention was paid to the evaluation of valvular leaks and the left ventricular wall thickness. Echocardiograms were obtained prior to implantation, at discharge and 1 month later. The patients' mean age was 77 ± 4 years. At discharge, 16 patients (76%) had aortic regurgitation: 8 grade I and 8 grade II. At 1 month, only 13 (62%) presented with the condition: 10 grade I and 3 grade II, with 8 patients (38%) demonstrating a reduction of at least one grade (P < .005). The septal thickness decreased (from 14.2 ± 2 mm at baseline to 11 ± 2.4 mm at 1 month; P < .001), as did the posterior wall thickness (from 10.9 ± 2.4 mm at baseline to 8.3 ± 1.2 mm at 1 month; P < .001). In our patient series, the frequency and grade of residual aortic regurgitation after implantation of the CoreValve prosthesis decreased within 1 month, and favorable left ventricular remodeling was also observed.
    Revista Espa de Cardiologia 01/2011; 64(1):67-70. · 3.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Provisional side-branch stenting is currently the most widely accepted percutaneous technique for the treatment of bifurcation lesions. However, abrupt closure of the side branch may occur after main vessel stent implantation. Resolving side-branch stenosis under these conditions may pose major technical difficulties. We describe a new technique to resolve uncrossable side-branch occlusion following main-vessel stent implantation during provisional side-branch stenting. The technique consists of using the jailed wire to dilate the occluded side branch. We first use a low profile, 1.25-mm diameter balloon catheter. A regular balloon is then inflated through the same wire to open the side branch, crushing the proximal part of the main vessel stent. At this point, a second stent is implanted at the side-branch, finishing the procedure as an inverted crush stenting. The described strategy may be useful in cases of uncrossable side-branch occlusion causing severe hemodynamic impairment that cannot be swiftly managed with conventional methods.Full English text available from: www.revespcardiol.org
    Revista Espanola De Cardiologia - REV ESPAN CARDIOL. 01/2011; 64(8):718-722.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report our experience with the Venture wire-control catheter in 20 patients with bifurcation lesions in which it was impossible to access the side branch using conventional techniques. This device was always used as a last resort and was employed during different stages in the treatment of the bifurcation lesions (i.e. initially, after stenting of the main vessel or both). In 17 patients (85%), use of the Venture catheter resulted in the success of the procedure. Only one complication associated with a monorail catheter was recorded. It was resolved successfully. One patient died from heart failure 10 days after the procedure and two patients, in whom it was impossible to access the side branch, had non-Q-wave myocardial infarctions. In conclusion, the Venture catheter was effective and safe, and enabled the side branches of complex bifurcation lesions to be accessed.
    Revista Espa de Cardiologia 12/2010; 63(12):1487-91. · 3.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have shown that intracoronary infusion of mononuclear bone marrow cells improves ventricular function in patients with acute myocardial infarction. However, less information is available about the use of this therapy during the chronic phase of a myocardial infarction. This study involved an analysis of the clinical, echocardiographic and angiographic changes observed in 19 patients with a revascularized chronic anterior myocardial infarction and depressed ventricular function who were treated by cell therapy. A series of patients were monitored during treatment and 6 months and 1 year after treatment. Autologous bone marrow was obtained by needle aspiration of the iliac crest and mononuclear cells were isolated by density-gradient centrifugation. An in vitro biological study of a sample of the infused cells was performed using fluorocytometry, phenotype marking and an analysis of the chemotactic properties of the cells. Six months and 1 year after cell therapy, a modest improvement was observed in clinical status and ventricular function, which was most pronounced in the group of patients who responded. Characteristically, these patients were revascularized close to the time of cell therapy. There was an inverse relationship between functional recovery and biological parameters that reflected a state conducive to cell migration. The intracoronary infusion of mononuclear bone marrow cells into patients with chronic anterior myocardial infarction appeared to result in a modest clinical and functional improvement after 6 months which was sustained up to 1 year after treatment.
    Revista Espa de Cardiologia 10/2010; 63(10):1127-35. · 3.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to describe early experience and medium-term follow-up with the CoreValve self-expanding aortic prosthesis at three Spanish hospitals. The study included patients with severe symptomatic aortic stenosis. Other inclusion criteria were: aortic valve area <1 cm(2) (<0.6 cm(2)/m(2)); aortic valve annulus diameter in the range 20-27 mm; diameter of the ascending aorta at the level of the sinotubular junction < or = 40 mm (small prosthesis) or < or = 43 mm (large prosthesis), and femoral artery diameter >6 mm. The study included 108 patients with a mean age of 78.6 + or - 6.7 years, a mean aortic valve area of 0.63 + or - 0.2 cm(2) and a mean logistic EuroSCORE of 16% + or - 13.9% (range, 2.27%-86.4%). After valve implantation, the maximum echocardiographic transaortic valve gradient decreased from 83.8 + or - 23 to 12.6 + or - 6 mmHg. No patient presented with greater than grade-2 residual aortic regurgitation on angiography. The procedural success rate was 98.1%. No patient died during the procedure. Definitive pacemaker implantation was carried out for atrioventricular block in 38 patients (35.2%). At 30 days, all-cause mortality and the rate of the combined endpoint of death, stroke, myocardial infarction or referral for surgery were 7.4% and 8.3%, respectively. The estimated 1-year survival rate calculated using the Kaplan-Meier method was 82.3% (for a median follow-up period of 7.6 months). Our early experience indicates that percutaneous aortic valve replacement is a safe and practical therapeutic option for patients with severe aortic stenosis who are at a high surgical risk.
    Revista Espa de Cardiologia 02/2010; 63(2):141-8. · 3.20 Impact Factor
  • Revista Espanola De Cardiologia - REV ESPAN CARDIOL. 01/2010; 63(12):1487-1491.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction and objectives The aim of the study was to describe early experience and medium-term follow-up with the CoreValve® self-expanding aortic prosthesis at three Spanish hospitals. Methods The study included patients with severe symptomatic aortic stenosis. Other inclusion criteria were: aortic valve area <1 cm2 (<0.6 cm2/m2); aortic valve annulus diameter in the range 20-27 mm; diameter of the ascending aorta at the level of the sinotubular junction ≤40 mm (small prosthesis) or ≤43 mm (large prosthesis), and femoral artery diameter >6 mm. Results The study included 108 patients with a mean age of 78.6±6.7 years, a mean aortic valve area of 0.63±0.2 cm2 and a mean logistic EuroSCORE of 16%±13.9% (range, 2.27%-86.4%). After valve implantation, the maximum echocardiographic transaortic valve gradient decreased from 83.8±23 to 12.6±6 mmHg. No patient presented with greater than grade-2 residual aortic regurgitation on angiography. The procedural success rate was 98.1%. No patient died during the procedure. Definitive pacemaker implantation was carried out for atrioventricular block in 38 patients (35.2%). At 30 days, all-cause mortality and the rate of the combined endpoint of death, stroke, myocardial infarction or referral for surgery were 7.4% and 8.3%, respectively. The estimated 1-year survival rate calculated using the Kaplan-Meier method was 82.3% (for a median follow-up period of 7.6 months). Conclusions Our early experience indicates that percutaneous aortic valve replacement is a safe and practical therapeutic option for patients with severe aortic stenosis who are at a high surgical risk.
    Revista Espanola De Cardiologia - REV ESPAN CARDIOL. 01/2010; 63(2):141-148.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction and objectives Studies have shown that intracoronary infusion of mononuclear bone marrow cells improves ventricular function in patients with acute myocardial infarction. However, less information is available about the use of this therapy during the chronic phase of a myocardial infarction. This study involved an analysis of the clinical, echocardiographic and angiographic changes observed in 19 patients with a revascularized chronic anterior myocardial infarction and depressed ventricular function who were treated by cell therapy. Methods A series of patients were monitored during treatment and 6 months and 1 year after treatment. Autologous bone marrow was obtained by needle aspiration of the iliac crest and mononuclear cells were isolated by density-gradient centrifugation. An in vitro biological study of a sample of the infused cells was performed using fluorocytometry, phenotype marking and an analysis of the chemotactic properties of the cells. Results Six months and 1 year after cell therapy, a modest improvement was observed in clinical status and ventricular function, which was most pronounced in the group of patients who responded. Characteristically, these patients were revascularized close to the time of cell therapy. There was an inverse relationship between functional recovery and biological parameters that reflected a state conducive to cell migration. Conclusions The intracoronary infusion of mononuclear bone marrow cells into patients with chronic anterior myocardial infarction appeared to result in a modest clinical and functional improvement after 6 months which was sustained up to 1 year after treatment.
    Revista Espanola De Cardiologia - REV ESPAN CARDIOL. 01/2010; 63(10):1127-1135.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is difficult to distinguish the effects early revascularization and regenerative therapy have on left ventricular function in patients with acute myocardial infarction (AMI). This study was an investigation into three groups of patients who had a revascularized anterior wall AMI and depressed left ventricular function (i.e., ejection fraction < 45%). The aim was to compare changes in left ventricular function between patients who received regenerative therapy and those who did not. Patients were randomly assigned to receive either an intracoronary infusion of autologous mononuclear bone marrow cells (Group I; n=10) or systemic administration of granulocyte colony-stimulating factor (G-CSF) (Group II; n=10), or to a control group (Group III; n=10). In Group I, intracoronary infusion was carried out 7(2) days after AMI. Group-II patients received a 10-day course of subcutaneous G-CSF injections, 10 .g/kg per day starting 5 days after AMI. Ventricular function was assessed at baseline and 3-month follow-up. A 20% increase in mean ejection fraction was observed in Group I, compared with increases of 4% (P<.01) and 6% (P<.05) in Groups II and III, respectively. Intracoronary infusion of mononuclear bone marrow cells in patients with AMI and poor ventricular function was associated with better short-term functional recovery than previously reported. However, mobilization of stem cells by G-CSF did not have a significant influence on functional recovery.
    Revista Espa de Cardiologia 05/2007; 60(4):357-65. · 3.20 Impact Factor

Publication Stats

1k Citations
221.77 Total Impact Points

Institutions

  • 1990–2014
    • Hospital Universitario Reina Sofía
      Cordoue, Andalusia, Spain
  • 1999–2011
    • University of Cordoba (Spain)
      Cordoue, Andalusia, Spain
  • 2003–2005
    • Hospital Universitario "Doctor Negrín"
      Las Palmas, Canary Islands, Spain
  • 1991–1999
    • Universidad de Las Palmas de Gran Canaria
      Las Palmas, Canary Islands, Spain
  • 1991–1993
    • Hospital Nuestra Señora del Rosario
      Madrid, Madrid, Spain